Greenwich Pharmaceuticals Inc. reported Wednesday that ithas started Phase II clinical trials on its carbohydrate drug fortreating rheumatoid arthritis.
The compound, GW-80126, is one of the Fort Washington, Pa.,company's second-generation synthetic monosaccharides thatexhibits anti-inflammatory and anti-proliferative properties.
Edwin Thompson, Greenwich's (NASDAQ:GRPI) president andchief executive officer, stressed the speed with which thecompany hopes to determine the drug's efficacy.
"To accomplish this goal, we have increased and strengthenedour internal clinical monitoring and data managementcapabilities," Thompson said.
"We are convinced that the cost to accelerate a drug'sdevelopment is insignificant compared to the cost of being lateto market."
(c) 1997 American Health Consultants. All rights reserved.